ROMURTIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C43H78N6O13
Molecular Weight	887.1118
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@](O[C@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)N[C@@H](CCCCNC(=O)CCCCCCCCCCCCCCCCC)C(O)=O)C(N)=O)([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O

InChI

InChIKey=IKSJCVFYCIKDTB-GZZWOGMVSA-N

InChI=1S/C43H78N6O13/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23-36(54)45-26-21-20-22-33(43(60)61)48-37(55)25-24-32(40(44)57)49-41(58)29(2)46-42(59)30(3)62-39(38(56)35(53)28-51)34(27-50)47-31(4)52/h27,29-30,32-35,38-39,51,53,56H,5-26,28H2,1-4H3,(H2,44,57)(H,45,54)(H,46,59)(H,47,52)(H,48,55)(H,49,58)(H,60,61)/t29-,30+,32+,33-,34-,35+,38+,39+/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11367521
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/3190791 and http://www.ncbi.nlm.nih.gov/pubmed/3263868

Romurtide (Muroctasin) is a non-specific immune stimulant derived from muramyl dipeptide, which is obtained from gram-positive bacterial cell walls. Muroctasin stimulates macrophages, which release interleukin-l, which in turn increases production of colony-stimulating factors; muroctasin also evokes an increased production of neutrophils. It is used in Japan for chemotherapy-induced leukopenia.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Interleukin-1 beta 22 Target ID: CHEMBL1909490 Sources: http://www.ncbi.nlm.nih.gov/pubmed/7928300	Activator 1430
TNF-alpha 18 Target ID: CHEMBL1825 Sources: http://www.ncbi.nlm.nih.gov/pubmed/7928300	Activator 1430
Interleukin-1 receptor antagonist protein 1 Target ID: P18510 Gene ID: 3557.0 Gene Symbol: IL1RN Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/7928300	Activator 1430
Granulocyte colony-stimulating factor 1 Target ID: P09919 Gene ID: 1440.0 Gene Symbol: CSF3 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/1705535	Activator 1430

Conditions

Condition	Modality	Highest Phase	Product
Leukopenia caused by anticancer chemotherapy in malignant lymphoma 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3058133	Secondary	Approved 8429	Muroctasin Approved Use Cancer Launch Date 1991
Leukopenia caused by anticancer chemotherapy in lung cancer 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3142367	Secondary	Approved 8429	Muroctasin Approved Use Cancer Launch Date 1991
Malignant pleurisy associated with lung cancer 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10688489	Primary	Approved 8429	Muroctasin Approved Use Cancer Launch Date 1991

PubMed

Title	Date	PubMed
Phase I study and clinical pharmacological study of muroctasin.	1988 Jul	3263868
Production of colony-stimulating factor from macrophages by muroctasin.	1988 Jul	3263870

Patents

Sample Use Guides

In Vivo Use Guide

For the treatment of leukopenia and thrombopenia 200 ug of Romurtide (muroctasin) for 6 days post-chemotherapy.

Route of Administration: Intravenous

In Vitro Use Guide

More than 1 ng/ml- of romurtide was needed to induce IL-1b and TNF, in contrast, only 0.1 ng/ml of the compound induced the substantial level of IL-8 in monkey PBMCs .

Name

Type

Language

ROMURTIDE

Official Name

English

2-ACETAMIDO-3-O-((R)-1-(((S)-1-(((R)-1-CARBAMOYL-3-(((S)-1-CARBOXY-5-STEARAMIDOPENTYL)CARBAMOYL)PROPYL)CARBAMOYL)ETHYL)CARBAMOYL)ETHYL)-2-DEOXY-D-GLUCOPYRANOSE

Common Name

English

ROMURTIDE [JAN]

Common Name

English

NOPIA

Brand Name

English

romurtide [INN]

Common Name

English

Romurtide [WHO-DD]

Common Name

English

ROMURTIDE [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C201